A Cell Therapy that Targets Gene Loss with a Logic-Gate to Differentiate Between Normal and Tumor Cells

Time: 2:00 pm
day: Day 1 - Track A - Lunch


  • The problem: Targeting cell therapies to solid tumors
  • The solution: Engineering a dual signal-integration mechanism (Tmod) that exploits loss of heterozygosity to distinguish between normal and tumor cells
  • The evidence: in vitro and in vivo studies with CEA and MSLN to support safety and efficacy for a Tmod logicgated cell therapy
  • The platform can be readily extended to other antigens